Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT04786600
Previous Study | Return to List | Next Study

A Phase II Randomized Therapeutic Optimization Trial for Subjects With Refractory Metastatic Colorectal Cancer Using ctDNA: Rapid 1 Trial

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04786600
Recruitment Status : Recruiting
First Posted : March 8, 2021
Last Update Posted : November 16, 2021
Sponsor:
Collaborator:
Natera, Inc.
Information provided by (Responsible Party):
University of Florida

Brief Summary:
This randomized, phase 2 study will investigate the use of the Signatera ctDNA assay versus the standard scan-based approach to guide treatment in patients with metastatic colorectal cancer. The aim of this study will be to measure and compare the overall survival, progression-free survival, and best overall response while on study of patients whose treatment has been guided by these two approaches.

Condition or disease Intervention/treatment Phase
Metastatic Colorectal Cancer Device: Signatera ctDNA assay Drug: pre-specified sequence of FDA-approved drugs and drug combinations Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 78 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Randomized Therapeutic Optimization Trial for Subjects With Refractory Metastatic Colorectal Cancer Using ctDNA: Rapid 1 Trial
Actual Study Start Date : November 4, 2021
Estimated Primary Completion Date : May 2024
Estimated Study Completion Date : May 2025

Arm Intervention/treatment
Experimental: ctDNA assay-guided intervention
Subjects on this arm will be tested with the Signatera ctDNA assay while receiving treatment on a pre-specified sequence of FDA-approved drugs and drug combinations. Subjects will move through this sequence based on the results of the ctDNA assay. Subjects will move to a new drug or drug combination in the sequence when the ctDNA assay indicates a significant increase in ctDNA level. Subjects will also have imaging scans every 12 weeks while on each drug or drug combination and subjects will move to a new drug or drug combination if these scans indicate disease progression.
Device: Signatera ctDNA assay
Subjects will be tested with the Signatera ctDNA assay every 2 weeks.

Drug: pre-specified sequence of FDA-approved drugs and drug combinations
Subjects will receive treatment with a pre-specified sequence of FDA-approved drugs and drug combinations

Active Comparator: Scan-guided Intervention
Subjects on this arm will be treated with the same pre-specified sequence of FDA-approved drugs and drug combinations as those on the ctDNA assay- guided intervention arm. Subjects will move through the sequence based on the results of imaging scans, moving to a new drug or drug combination if imaging shows progressive disease.
Drug: pre-specified sequence of FDA-approved drugs and drug combinations
Subjects will receive treatment with a pre-specified sequence of FDA-approved drugs and drug combinations




Primary Outcome Measures :
  1. Overall survival [ Time Frame: 1 year ]
    Compare the overall survival in subjects who receive ctDNA assay-guided treatment and scan-guided treatment


Secondary Outcome Measures :
  1. Progression free survival [ Time Frame: 1 year ]
    Compare the progression free survival in subjects who receive ctDNA assay-guided treatment and scan-guided treatment

  2. Best overall response [ Time Frame: 1 year ]
    Compare the proportion of subjects having each category of response during study participation (complete response, partial response, stable disease, and progressive disease) per RECIST v1.1 criteria



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 99 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically confirmed adenocarcinoma of the colon or rectum with metastatic disease measurable by RECIST v1.1 and not currently a candidate for oligometastatic definitive management
  • Must have progressed or have demonstrated intolerance to first line therapy for metastatic disease. Individuals who recurred within 6 months of completion of oxaliplatin based adjuvant chemotherapy are also eligible.
  • Subjects must have tissue from either the primary and/or metastatic deposit available for submission at enrollment. Tissue can be from either a biopsy or resection surgery, whichever is most recent, but must be from the past five years.
  • Subjects must have measurable ctDNA, as detected by the Signatera ctDNA assay at time of sample analysis
  • Subjects must have had molecular profiling to determine tumor RAS, BRAF and MMR/MSI status
  • Subjects with known or suspected Gilbert's disease must be formally tested for UGT1A1*28 with results available to study team prior to treatment initiation
  • Any clinically relevant (as deemed by the PI) adverse events related to prior therapies must have resolved to Grade 1 or less (CTCAE 5.0) at study enrollment
  • Age ≥18 years
  • ECOG performance status of 0-2
  • Life expectancy of at least 6 months
  • Adequate organ function, as defined as:

    • Absolute neutrophil count (ANC) ≥ 1,500/µL
    • Hemoglobin ≥ 9g/dL
    • Platelets ≥ 100,000/µL
    • Total bilirubin ≤ 1.5 ULN or direct bilirubin ≤ 1 x ULN
    • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN; if liver metastases present, then AST and ALT must be ≤ 5 x ULN
    • Serum creatinine ≤ 1.5 x ULN or calculated creatinine clearance ≥ 59 mL/min/1.73m using Cockcroft-Gault equation
  • Subjects must not have more than one active malignancy at the time of enrollment (Subjects with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen [as determined by the treating physician and approved by the PI] may be included).
  • Women of childbearing potential must be using an adequate method of contraception to avoid pregnancy throughout the study and for at least 12 weeks after the end of protocol-specified treatment to minimize the risk of pregnancy.
  • Males with female partners of child-bearing potential must agree to use physician-approved contraceptive methods throughout the study and should avoid conceiving children for 12 weeks following the last dose of the protocol-specified treatment.
  • Written informed consent obtained from the subject and the subject agrees to comply with all the study related procedures

Exclusion Criteria:

  • Colorectal cancer known to be Microsatellite High (MSI-H), deficient in DNA mismatch repair genes (dMMR), or BRAF (V600E) mutated
  • Females or males of childbearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for at least 12 weeks after the last dose of the protocol-specified treatment
  • Females who are pregnant or breastfeeding
  • History of any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of protocol therapy or that might affect the interpretation of the results of the study or that puts the subject at high risk for treatment complications, in the opinion of the treating physician
  • Prisoners or subjects who are involuntarily incarcerated, or subjects who are compulsorily detained for treatment of either a psychiatric or physical illness
  • Prior radiation therapy must have been completed 14 days prior to study entry
  • Prior chemotherapy or biologic therapy must have been completed 21 days prior to study entry
  • Known Dihydropyrimidine Dehydrogenase (DPD) deficiency

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04786600


Contacts
Layout table for location contacts
Contact: Alexandra Mueller, MS 352-273-9785 PMO@cancer.ufl.edu

Locations
Layout table for location information
United States, Florida
University of Florida Recruiting
Gainesville, Florida, United States, 32608
Contact: Jack Bates    352-265-5121    jbates1@ufl.edu   
Sponsors and Collaborators
University of Florida
Natera, Inc.
Investigators
Layout table for investigator information
Principal Investigator: Sherise Rogers, MD University of Florida
Layout table for additonal information
Responsible Party: University of Florida
ClinicalTrials.gov Identifier: NCT04786600    
Other Study ID Numbers: UF-STO-GI-012
UF-STO-GI-012 ( Other Identifier: University of Florida )
IRB202100341 ( Other Identifier: University of Florida )
OCR40199 ( Other Identifier: University of Florida )
First Posted: March 8, 2021    Key Record Dates
Last Update Posted: November 16, 2021
Last Verified: November 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Product Manufactured in and Exported from the U.S.: No
Keywords provided by University of Florida:
metastatic colorectal cancer
precision oncology
personalized medicine
ctDNA
Additional relevant MeSH terms:
Layout table for MeSH terms
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases